Galip Büyükturan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Galip Büyükturan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Remzi Ekici
Department of Gastroenterology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye
3 shared publications - Tolga Bakır
Department of Gastroenterology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkiye
2 shared publications - Ahmet Fatih Köse1 shared publication
- Ahmet Karadaş1 shared publication
- Ali Gokhan Akcay
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkiye
1 shared publication - Ali Selcuk
Division of Immunology and Allergic Diseases, Ankara Gulhane Training and Research Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- 18 August 2026
- Published by Academician Publishing
- p. 565-574
Karaciğer Biyopsisi
Yeterli oral alımın sağlanamadığı, ancak gastrointestinal sistemin işlevini koruduğu hastalarda enteral beslenme, parenteral beslenmeye kıyasla daha fizyolojik, daha güvenli ve daha düşük maliyetli bir destek yöntemidir. Dört haftadan uzun süreli beslenme gereksinimi öngörülen olgularda perkütan endoskopik gastrostomi (PEG), uzun süreli enteral erişim için altın standart yöntem olarak kabul edilmektedir. Nörolojik disfaji (inme, amiyotrofik lateral skleroz, ilerlemiş Parkinson hastalığı), baş-boyun ve özofagus kanserleri ile ciddi kraniofasiyal travma başlıca endikasyonları oluşturur. Daha distal beslenme gerektiren, mide boşalması ileri derecede bozulmuş veya yüksek aspirasyon riski taşıyan olgularda, PEG tüpünden geçirilen jejunal uzantı (PEG-J) ya da doğrudan perkütan endoskopik jejunostomi (D-PEJ) tercih edilir. Avrupa Gastrointestinal Endoskopi Derneği (ESGE) kılavuzları, standart yöntem olarak “çekme (pull)” tekniğini önermekte; özofagus darlığı, baş-boyun veya özofagus kanseri gibi geçişin güç olduğu durumlarda “itme (push/ introducer)” tekniğini, tümör ekimi (seeding) riskini azaltmak amacıyla tercih etmektedir. İşlemden 30 dakika önce tek doz intravenöz beta-laktam antibiyotik profilaksisi yara enfeksiyonunu anlamlı biçimde azaltır. Güncel ASGE kılavuzu, gastrostomi beslenmesine işlemden sonraki dört saat içinde güvenle başlanabileceğini ve antiplatelet ilaçların kesilmesine genellikle gerek olmadığını bildirmektedir. Bu bölüm; PEG/PEJ/PEG-J endikasyonlarını, kontrendikasyonlarını, uygulama tekniklerini, komplikasyonlarını ve takip ilkelerini kanıta dayalı güncel kılavuzlar çerçevesinde ele almakta; hasta bilgilendirme metinleri, sık sorulan sorular ve acil başvuru ölçütlerini içermektedir. In patients who cannot maintain adequate oral intake but have a functioning gastrointestinal tract, enteral nutrition is more physiological, safer, and less costly than parenteral nutrition. Percutaneous endoscopic gastrostomy (PEG) is the gold-standard method for long-term enteral access when feeding is anticipated to be required for more than four weeks. The principal indications are neurological dysphagia (stroke, amyotrophic lateral sclerosis, advanced Parkinson's disease), head-and-neck and esophageal malignancies, and severe craniofacial trauma. When more distal feeding is required because of severely impaired gastric emptying or a high aspiration risk, a jejunal extension through the PEG (PEG-J) or a direct percutaneous endoscopic jejunostomy (D-PEJ) is preferred. The European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend the “pull” technique as the standard method and the “push/introducer” technique when transoral passage is difficult, such as in esophageal stenosis or head-and-neck/esophageal cancer, in order to reduce the risk of tumor seeding. A single intravenous dose of a beta-lactam antibiotic 30 minutes before the procedure significantly reduces wound infection. The current ASGE guideline states that tube feeding can be safely started within four hours of gastrostomy and that antiplatelet agents generally need not be withheld. This chapter reviews the indications, contraindications, procedural techniques, complications, and follow-up principles of PEG/PEJ/PEG-J within the framework of current evidence-based guidelines, and provides patient education texts, frequently asked questions, and red-flag criteria.
- 18 August 2026
- Published by Academician Publishing
- p. 565-574
Karaciğer Biyopsisi
Yeterli oral alımın sağlanamadığı, ancak gastrointestinal sistemin işlevini koruduğu hastalarda enteral beslenme, parenteral beslenmeye kıyasla daha fizyolojik, daha güvenli ve daha düşük maliyetli bir destek yöntemidir. Dört haftadan uzun süreli beslenme gereksinimi öngörülen olgularda perkütan endoskopik gastrostomi (PEG), uzun süreli enteral erişim için altın standart yöntem olarak kabul edilmektedir. Nörolojik disfaji (inme, amiyotrofik lateral skleroz, ilerlemiş Parkinson hastalığı), baş-boyun ve özofagus kanserleri ile ciddi kraniofasiyal travma başlıca endikasyonları oluşturur. Daha distal beslenme gerektiren, mide boşalması ileri derecede bozulmuş veya yüksek aspirasyon riski taşıyan olgularda, PEG tüpünden geçirilen jejunal uzantı (PEG-J) ya da doğrudan perkütan endoskopik jejunostomi (D-PEJ) tercih edilir. Avrupa Gastrointestinal Endoskopi Derneği (ESGE) kılavuzları, standart yöntem olarak “çekme (pull)” tekniğini önermekte; özofagus darlığı, baş-boyun veya özofagus kanseri gibi geçişin güç olduğu durumlarda “itme (push/ introducer)” tekniğini, tümör ekimi (seeding) riskini azaltmak amacıyla tercih etmektedir. İşlemden 30 dakika önce tek doz intravenöz beta-laktam antibiyotik profilaksisi yara enfeksiyonunu anlamlı biçimde azaltır. Güncel ASGE kılavuzu, gastrostomi beslenmesine işlemden sonraki dört saat içinde güvenle başlanabileceğini ve antiplatelet ilaçların kesilmesine genellikle gerek olmadığını bildirmektedir. Bu bölüm; PEG/PEJ/PEG-J endikasyonlarını, kontrendikasyonlarını, uygulama tekniklerini, komplikasyonlarını ve takip ilkelerini kanıta dayalı güncel kılavuzlar çerçevesinde ele almakta; hasta bilgilendirme metinleri, sık sorulan sorular ve acil başvuru ölçütlerini içermektedir. In patients who cannot maintain adequate oral intake but have a functioning gastrointestinal tract, enteral nutrition is more physiological, safer, and less costly than parenteral nutrition. Percutaneous endoscopic gastrostomy (PEG) is the gold-standard method for long-term enteral access when feeding is anticipated to be required for more than four weeks. The principal indications are neurological dysphagia (stroke, amyotrophic lateral sclerosis, advanced Parkinson's disease), head-and-neck and esophageal malignancies, and severe craniofacial trauma. When more distal feeding is required because of severely impaired gastric emptying or a high aspiration risk, a jejunal extension through the PEG (PEG-J) or a direct percutaneous endoscopic jejunostomy (D-PEJ) is preferred. The European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend the “pull” technique as the standard method and the “push/introducer” technique when transoral passage is difficult, such as in esophageal stenosis or head-and-neck/esophageal cancer, in order to reduce the risk of tumor seeding. A single intravenous dose of a beta-lactam antibiotic 30 minutes before the procedure significantly reduces wound infection. The current ASGE guideline states that tube feeding can be safely started within four hours of gastrostomy and that antiplatelet agents generally need not be withheld. This chapter reviews the indications, contraindications, procedural techniques, complications, and follow-up principles of PEG/PEJ/PEG-J within the framework of current evidence-based guidelines, and provides patient education texts, frequently asked questions, and red-flag criteria.
- 18 August 2026
- Published by Academician Publishing
- p. 541-552
Perkütan Endoskopik Gastrostomi (PEG), Jejunostomi (PEJ) ve PEG-J
Yeterli oral alımın sağlanamadığı, ancak gastrointestinal sistemin işlevini koruduğu hastalarda enteral beslenme, parenteral beslenmeye kıyasla daha fizyolojik, daha güvenli ve daha düşük maliyetli bir destek yöntemidir. Dört haftadan uzun süreli beslenme gereksinimi öngörülen olgularda perkütan endoskopik gastrostomi (PEG), uzun süreli enteral erişim için altın standart yöntem olarak kabul edilmektedir. Nörolojik disfaji (inme, amiyotrofik lateral skleroz, ilerlemiş Parkinson hastalığı), baş-boyun ve özofagus kanserleri ile ciddi kraniofasiyal travma başlıca endikasyonları oluşturur. Daha distal beslenme gerektiren, mide boşalması ileri derecede bozulmuş veya yüksek aspirasyon riski taşıyan olgularda, PEG tüpünden geçirilen jejunal uzantı (PEG-J) ya da doğrudan perkütan endoskopik jejunostomi (D-PEJ) tercih edilir. Avrupa Gastrointestinal Endoskopi Derneği (ESGE) kılavuzları, standart yöntem olarak “çekme (pull)” tekniğini önermekte; özofagus darlığı, baş-boyun veya özofagus kanseri gibi geçişin güç olduğu durumlarda “itme (push/ introducer)” tekniğini, tümör ekimi (seeding) riskini azaltmak amacıyla tercih etmektedir. İşlemden 30 dakika önce tek doz intravenöz beta-laktam antibiyotik profilaksisi yara enfeksiyonunu anlamlı biçimde azaltır. Güncel ASGE kılavuzu, gastrostomi beslenmesine işlemden sonraki dört saat içinde güvenle başlanabileceğini ve antiplatelet ilaçların kesilmesine genellikle gerek olmadığını bildirmektedir. Bu bölüm; PEG/PEJ/PEG-J endikasyonlarını, kontrendikasyonlarını, uygulama tekniklerini, komplikasyonlarını ve takip ilkelerini kanıta dayalı güncel kılavuzlar çerçevesinde ele almakta; hasta bilgilendirme metinleri, sık sorulan sorular ve acil başvuru ölçütlerini içermektedir. In patients who cannot maintain adequate oral intake but have a functioning gastrointestinal tract, enteral nutrition is more physiological, safer, and less costly than parenteral nutrition. Percutaneous endoscopic gastrostomy (PEG) is the gold-standard method for long-term enteral access when feeding is anticipated to be required for more than four weeks. The principal indications are neurological dysphagia (stroke, amyotrophic lateral sclerosis, advanced Parkinson's disease), head-and-neck and esophageal malignancies, and severe craniofacial trauma. When more distal feeding is required because of severely impaired gastric emptying or a high aspiration risk, a jejunal extension through the PEG (PEG-J) or a direct percutaneous endoscopic jejunostomy (D-PEJ) is preferred. The European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend the “pull” technique as the standard method and the “push/introducer” technique when transoral passage is difficult, such as in esophageal stenosis or head-and-neck/esophageal cancer, in order to reduce the risk of tumor seeding. A single intravenous dose of a beta-lactam antibiotic 30 minutes before the procedure significantly reduces wound infection. The current ASGE guideline states that tube feeding can be safely started within four hours of gastrostomy and that antiplatelet agents generally need not be withheld. This chapter reviews the indications, contraindications, procedural techniques, complications, and follow-up principles of PEG/PEJ/PEG-J within the framework of current evidence-based guidelines, and provides patient education texts, frequently asked questions, and red-flag criteria
- 18 August 2026
- Published by Academician Publishing
- p. 541-552
Perkütan Endoskopik Gastrostomi (PEG), Jejunostomi (PEJ) ve PEG-J
Yeterli oral alımın sağlanamadığı, ancak gastrointestinal sistemin işlevini koruduğu hastalarda enteral beslenme, parenteral beslenmeye kıyasla daha fizyolojik, daha güvenli ve daha düşük maliyetli bir destek yöntemidir. Dört haftadan uzun süreli beslenme gereksinimi öngörülen olgularda perkütan endoskopik gastrostomi (PEG), uzun süreli enteral erişim için altın standart yöntem olarak kabul edilmektedir. Nörolojik disfaji (inme, amiyotrofik lateral skleroz, ilerlemiş Parkinson hastalığı), baş-boyun ve özofagus kanserleri ile ciddi kraniofasiyal travma başlıca endikasyonları oluşturur. Daha distal beslenme gerektiren, mide boşalması ileri derecede bozulmuş veya yüksek aspirasyon riski taşıyan olgularda, PEG tüpünden geçirilen jejunal uzantı (PEG-J) ya da doğrudan perkütan endoskopik jejunostomi (D-PEJ) tercih edilir. Avrupa Gastrointestinal Endoskopi Derneği (ESGE) kılavuzları, standart yöntem olarak “çekme (pull)” tekniğini önermekte; özofagus darlığı, baş-boyun veya özofagus kanseri gibi geçişin güç olduğu durumlarda “itme (push/ introducer)” tekniğini, tümör ekimi (seeding) riskini azaltmak amacıyla tercih etmektedir. İşlemden 30 dakika önce tek doz intravenöz beta-laktam antibiyotik profilaksisi yara enfeksiyonunu anlamlı biçimde azaltır. Güncel ASGE kılavuzu, gastrostomi beslenmesine işlemden sonraki dört saat içinde güvenle başlanabileceğini ve antiplatelet ilaçların kesilmesine genellikle gerek olmadığını bildirmektedir. Bu bölüm; PEG/PEJ/PEG-J endikasyonlarını, kontrendikasyonlarını, uygulama tekniklerini, komplikasyonlarını ve takip ilkelerini kanıta dayalı güncel kılavuzlar çerçevesinde ele almakta; hasta bilgilendirme metinleri, sık sorulan sorular ve acil başvuru ölçütlerini içermektedir. In patients who cannot maintain adequate oral intake but have a functioning gastrointestinal tract, enteral nutrition is more physiological, safer, and less costly than parenteral nutrition. Percutaneous endoscopic gastrostomy (PEG) is the gold-standard method for long-term enteral access when feeding is anticipated to be required for more than four weeks. The principal indications are neurological dysphagia (stroke, amyotrophic lateral sclerosis, advanced Parkinson's disease), head-and-neck and esophageal malignancies, and severe craniofacial trauma. When more distal feeding is required because of severely impaired gastric emptying or a high aspiration risk, a jejunal extension through the PEG (PEG-J) or a direct percutaneous endoscopic jejunostomy (D-PEJ) is preferred. The European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend the “pull” technique as the standard method and the “push/introducer” technique when transoral passage is difficult, such as in esophageal stenosis or head-and-neck/esophageal cancer, in order to reduce the risk of tumor seeding. A single intravenous dose of a beta-lactam antibiotic 30 minutes before the procedure significantly reduces wound infection. The current ASGE guideline states that tube feeding can be safely started within four hours of gastrostomy and that antiplatelet agents generally need not be withheld. This chapter reviews the indications, contraindications, procedural techniques, complications, and follow-up principles of PEG/PEJ/PEG-J within the framework of current evidence-based guidelines, and provides patient education texts, frequently asked questions, and red-flag criteria
- 18 August 2026
- Published by Academician Publishing
- p. 553-564
İntragastrik Balon Yerleştirilmesi ve Çıkarılması
İntragastrik balon (İGB), yaşam tarzı değişikliklerine yeterli yanıt vermeyen obez bireylerde mide hacmini geçici olarak azaltarak kilo kaybını destekleyen, geri dönüşümlü ve minimal invaziv bir endoskopik bariyatrik araçtır. Üst endoskopi eşliğinde mideye yerleştirilen yumuşak silikon balon, sıvı veya hava ile şişirilerek hem mekanik kısıtlama hem de nörohumoral tokluk yanıtı oluşturur. Güncel ASGE–ESGE 2024 ortak kılavuzu; beden kitle indeksi (BKİ) ≥30 kg/m² olan ya da BKİ 27,0–29,9 kg/m² olup en az bir obeziteyle ilişkili komorbiditesi (tip 2 diyabet, hipertansiyon, obstrüktif uyku apnesi vb.) bulunan hastalarda, yaşam tarzı değişiklikleriyle birlikte İGB kullanımını önermektedir. İGB, tek başına bir tedavi değil; yapılandırılmış diyet, fiziksel aktivite ve davranış değişikliği programının etkinliğini güçlendiren bir araçtır. Sıvı dolu balonların içine eklenen metilen mavisi, olası bir sızıntı/rüptür durumunda idrar renginin değişmesiyle erken uyarı sağlar. Sıvı dolu klasik balonlar genellikle altıncı ayda endoskopik olarak çıkarılır; ayarlanabilir ve yutulabilir tipler farklı sürelerde kullanılabilir. En sık görülen yan etkiler ilk günlerdeki bulantı, kusma ve karın krampları olup, bunlar antiemetik ve proton pompası inhibitörü (PPİ) ile yönetilir; ciddi ancak seyrek komplikasyonlar arasında balon migrasyonuna bağlı bağırsak tıkanması, mide ülseri/perforasyonu ve pankreatit yer alır. Bu bölüm; İGB endikasyonlarını, kontrendikasyonlarını, etkinlik ve güvenlik verilerini, yerleştirme/çıkarma tekniklerini ve hasta iletişimini güncel kanıtlar ışığında ele almaktadır. The intragastric balloon (IGB) is a reversible, minimally invasive endoscopic bariatric device that supports weight loss by temporarily reducing gastric volume in patients with obesity who have not responded adequately to lifestyle interventions. Placed under upper endoscopy, the soft silicone balloon is inflated with fluid or air, producing both mechanical restriction and a neurohumoral satiety response. The current ASGE–ESGE 2024 joint guideline suggests the use of IGB together with lifestyle modification in patients with a body mass index (BMI) ≥30 kg/m², or 27.0–29.9 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, etc.). The IGB is not a stand-alone therapy but a tool that augments a structured diet, physical activity, and behavioral program. Methylene blue added to fluid-filled balloons provides an early warning of leakage/rupture through a change in urine color. Classic fluid-filled balloons are generally removed endoscopically at six months; adjustable and swallowable types may remain for different durations. The most common adverse effects are nausea, vomiting, and abdominal cramps in the first days, managed with antiemetics and a proton pump inhibitor (PPİ); rare but serious complications include bowel obstruction from balloon migration, gastric ulcer/perforation, and pancreatitis. This chapter reviews IGB indications, contraindications, efficacy and safety data, placement/ removal techniques, and patient communication in light of current evidence.
- 18 August 2026
- Published by Academician Publishing
- p. 553-564
İntragastrik Balon Yerleştirilmesi ve Çıkarılması
İntragastrik balon (İGB), yaşam tarzı değişikliklerine yeterli yanıt vermeyen obez bireylerde mide hacmini geçici olarak azaltarak kilo kaybını destekleyen, geri dönüşümlü ve minimal invaziv bir endoskopik bariyatrik araçtır. Üst endoskopi eşliğinde mideye yerleştirilen yumuşak silikon balon, sıvı veya hava ile şişirilerek hem mekanik kısıtlama hem de nörohumoral tokluk yanıtı oluşturur. Güncel ASGE–ESGE 2024 ortak kılavuzu; beden kitle indeksi (BKİ) ≥30 kg/m² olan ya da BKİ 27,0–29,9 kg/m² olup en az bir obeziteyle ilişkili komorbiditesi (tip 2 diyabet, hipertansiyon, obstrüktif uyku apnesi vb.) bulunan hastalarda, yaşam tarzı değişiklikleriyle birlikte İGB kullanımını önermektedir. İGB, tek başına bir tedavi değil; yapılandırılmış diyet, fiziksel aktivite ve davranış değişikliği programının etkinliğini güçlendiren bir araçtır. Sıvı dolu balonların içine eklenen metilen mavisi, olası bir sızıntı/rüptür durumunda idrar renginin değişmesiyle erken uyarı sağlar. Sıvı dolu klasik balonlar genellikle altıncı ayda endoskopik olarak çıkarılır; ayarlanabilir ve yutulabilir tipler farklı sürelerde kullanılabilir. En sık görülen yan etkiler ilk günlerdeki bulantı, kusma ve karın krampları olup, bunlar antiemetik ve proton pompası inhibitörü (PPİ) ile yönetilir; ciddi ancak seyrek komplikasyonlar arasında balon migrasyonuna bağlı bağırsak tıkanması, mide ülseri/perforasyonu ve pankreatit yer alır. Bu bölüm; İGB endikasyonlarını, kontrendikasyonlarını, etkinlik ve güvenlik verilerini, yerleştirme/çıkarma tekniklerini ve hasta iletişimini güncel kanıtlar ışığında ele almaktadır. The intragastric balloon (IGB) is a reversible, minimally invasive endoscopic bariatric device that supports weight loss by temporarily reducing gastric volume in patients with obesity who have not responded adequately to lifestyle interventions. Placed under upper endoscopy, the soft silicone balloon is inflated with fluid or air, producing both mechanical restriction and a neurohumoral satiety response. The current ASGE–ESGE 2024 joint guideline suggests the use of IGB together with lifestyle modification in patients with a body mass index (BMI) ≥30 kg/m², or 27.0–29.9 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, etc.). The IGB is not a stand-alone therapy but a tool that augments a structured diet, physical activity, and behavioral program. Methylene blue added to fluid-filled balloons provides an early warning of leakage/rupture through a change in urine color. Classic fluid-filled balloons are generally removed endoscopically at six months; adjustable and swallowable types may remain for different durations. The most common adverse effects are nausea, vomiting, and abdominal cramps in the first days, managed with antiemetics and a proton pump inhibitor (PPİ); rare but serious complications include bowel obstruction from balloon migration, gastric ulcer/perforation, and pancreatitis. This chapter reviews IGB indications, contraindications, efficacy and safety data, placement/ removal techniques, and patient communication in light of current evidence.
- 18 August 2026
- Published by Academician Publishing
Gastroenterolojide Hasta Bilgilendirme Rehberi
- 18 August 2026
- Published by Academician Publishing
- p. 575-584
Parasentez
İntragastrik balon (İGB), yaşam tarzı değişikliklerine yeterli yanıt vermeyen obez bireylerde mide hacmini geçici olarak azaltarak kilo kaybını destekleyen, geri dönüşümlü ve minimal invaziv bir endoskopik bariyatrik araçtır. Üst endoskopi eşliğinde mideye yerleştirilen yumuşak silikon balon, sıvı veya hava ile şişirilerek hem mekanik kısıtlama hem de nörohumoral tokluk yanıtı oluşturur. Güncel ASGE–ESGE 2024 ortak kılavuzu; beden kitle indeksi (BKİ) ≥30 kg/m² olan ya da BKİ 27,0–29,9 kg/m² olup en az bir obeziteyle ilişkili komorbiditesi (tip 2 diyabet, hipertansiyon, obstrüktif uyku apnesi vb.) bulunan hastalarda, yaşam tarzı değişiklikleriyle birlikte İGB kullanımını önermektedir. İGB, tek başına bir tedavi değil; yapılandırılmış diyet, fiziksel aktivite ve davranış değişikliği programının etkinliğini güçlendiren bir araçtır. Sıvı dolu balonların içine eklenen metilen mavisi, olası bir sızıntı/rüptür durumunda idrar renginin değişmesiyle erken uyarı sağlar. Sıvı dolu klasik balonlar genellikle altıncı ayda endoskopik olarak çıkarılır; ayarlanabilir ve yutulabilir tipler farklı sürelerde kullanılabilir. En sık görülen yan etkiler ilk günlerdeki bulantı, kusma ve karın krampları olup, bunlar antiemetik ve proton pompası inhibitörü (PPİ) ile yönetilir; ciddi ancak seyrek komplikasyonlar arasında balon migrasyonuna bağlı bağırsak tıkanması, mide ülseri/perforasyonu ve pankreatit yer alır. Bu bölüm; İGB endikasyonlarını, kontrendikasyonlarını, etkinlik ve güvenlik verilerini, yerleştirme/çıkarma tekniklerini ve hasta iletişimini güncel kanıtlar ışığında ele almaktadır. The intragastric balloon (IGB) is a reversible, minimally invasive endoscopic bariatric device that supports weight loss by temporarily reducing gastric volume in patients with obesity who have not responded adequately to lifestyle interventions. Placed under upper endoscopy, the soft silicone balloon is inflated with fluid or air, producing both mechanical restriction and a neurohumoral satiety response. The current ASGE–ESGE 2024 joint guideline suggests the use of IGB together with lifestyle modification in patients with a body mass index (BMI) ≥30 kg/m², or 27.0–29.9 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, etc.). The IGB is not a stand-alone therapy but a tool that augments a structured diet, physical activity, and behavioral program. Methylene blue added to fluid-filled balloons provides an early warning of leakage/rupture through a change in urine color. Classic fluid-filled balloons are generally removed endoscopically at six months; adjustable and swallowable types may remain for different durations. The most common adverse effects are nausea, vomiting, and abdominal cramps in the first days, managed with antiemetics and a proton pump inhibitor (PPİ); rare but serious complications include bowel obstruction from balloon migration, gastric ulcer/perforation, and pancreatitis. This chapter reviews IGB indications, contraindications, efficacy and safety data, placement/ removal techniques, and patient communication in light of current evidence.
- 18 August 2026
- Published by Academician Publishing
- p. 575-584
Parasentez
İntragastrik balon (İGB), yaşam tarzı değişikliklerine yeterli yanıt vermeyen obez bireylerde mide hacmini geçici olarak azaltarak kilo kaybını destekleyen, geri dönüşümlü ve minimal invaziv bir endoskopik bariyatrik araçtır. Üst endoskopi eşliğinde mideye yerleştirilen yumuşak silikon balon, sıvı veya hava ile şişirilerek hem mekanik kısıtlama hem de nörohumoral tokluk yanıtı oluşturur. Güncel ASGE–ESGE 2024 ortak kılavuzu; beden kitle indeksi (BKİ) ≥30 kg/m² olan ya da BKİ 27,0–29,9 kg/m² olup en az bir obeziteyle ilişkili komorbiditesi (tip 2 diyabet, hipertansiyon, obstrüktif uyku apnesi vb.) bulunan hastalarda, yaşam tarzı değişiklikleriyle birlikte İGB kullanımını önermektedir. İGB, tek başına bir tedavi değil; yapılandırılmış diyet, fiziksel aktivite ve davranış değişikliği programının etkinliğini güçlendiren bir araçtır. Sıvı dolu balonların içine eklenen metilen mavisi, olası bir sızıntı/rüptür durumunda idrar renginin değişmesiyle erken uyarı sağlar. Sıvı dolu klasik balonlar genellikle altıncı ayda endoskopik olarak çıkarılır; ayarlanabilir ve yutulabilir tipler farklı sürelerde kullanılabilir. En sık görülen yan etkiler ilk günlerdeki bulantı, kusma ve karın krampları olup, bunlar antiemetik ve proton pompası inhibitörü (PPİ) ile yönetilir; ciddi ancak seyrek komplikasyonlar arasında balon migrasyonuna bağlı bağırsak tıkanması, mide ülseri/perforasyonu ve pankreatit yer alır. Bu bölüm; İGB endikasyonlarını, kontrendikasyonlarını, etkinlik ve güvenlik verilerini, yerleştirme/çıkarma tekniklerini ve hasta iletişimini güncel kanıtlar ışığında ele almaktadır. The intragastric balloon (IGB) is a reversible, minimally invasive endoscopic bariatric device that supports weight loss by temporarily reducing gastric volume in patients with obesity who have not responded adequately to lifestyle interventions. Placed under upper endoscopy, the soft silicone balloon is inflated with fluid or air, producing both mechanical restriction and a neurohumoral satiety response. The current ASGE–ESGE 2024 joint guideline suggests the use of IGB together with lifestyle modification in patients with a body mass index (BMI) ≥30 kg/m², or 27.0–29.9 kg/m² with at least one obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, etc.). The IGB is not a stand-alone therapy but a tool that augments a structured diet, physical activity, and behavioral program. Methylene blue added to fluid-filled balloons provides an early warning of leakage/rupture through a change in urine color. Classic fluid-filled balloons are generally removed endoscopically at six months; adjustable and swallowable types may remain for different durations. The most common adverse effects are nausea, vomiting, and abdominal cramps in the first days, managed with antiemetics and a proton pump inhibitor (PPİ); rare but serious complications include bowel obstruction from balloon migration, gastric ulcer/perforation, and pancreatitis. This chapter reviews IGB indications, contraindications, efficacy and safety data, placement/ removal techniques, and patient communication in light of current evidence.
- Open Access
- 30 July 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (7) , 167-176
Evaluation of Plasma Catestatin Levels in Patients with Heart Failure: A Cross-Sectional Analytical Study
Objective: Heart failure (HF) is a common and potentially fatal clinical condition. Catestatin, a peptide derived from chromogranin A (CgA), inhibits catecholamine secretion. This study aimed to evaluate differences in plasma catestatin levels between individuals without HF and patients with HF, and to investigate the relationship between catestatin and established HF markers. GB, RE, IE, BY, RA, TO, FNA, KS Methods: A total of 60 HF patients with left ventricular ejection fraction (LVEF) ≤45% and 53 control subjects matched for factors that could influence catestatin levels were included. The absence of heart failure in control participants was confirmed by clinical assessment, review of medical records and transthoracic echocardiography. Plasma samples were collected simultaneously in aprotinin-containing tubes to prevent peptide degradation. Plasma catestatin levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: Catestatin levels were significantly higher in patients with HF (45.46 ± 16.69 ng/mL) compared with individuals without HF (37.15 ± 16.36 ng/mL) (t = 2.69, p = 0.008). Catestatin levels increased significantly with advancing NYHA functional class (Jonckheere–Terpstra test: J-T = 2.19; p = 0.029). Catestatin was positively correlated with NT-proBNP (r = 0.241; p = 0.010) and negatively correlated with LVEF (r = −0.19; p = 0.043). Catestatin was lower in patients with left ventricular hypertrophy than in those without, both within the patient group (41.39 ± 16.69 versus 49.64 ± 15.09 ng/mL; p = 0.04) and across the whole study population (37.41 ± 16.22 versus 44.04 ± 15.48 ng/mL; p = 0.03). The area under the ROC curve for catestatin in HF diagnosis was 0.635. Conclusion: Catestatin levels are associated with the presence and severity of heart failure. Its correlation with established parameters of severity and its progressive increase across NYHA functional classes indicate that catestatin may have value as a complementary neurohumoral marker in heart failure. Because the design was cross-sectional, no inference can be drawn regarding prognostic utility, and prospective evaluation is required.
- 30 July 2026
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 13 (7) , 167-176
Open AccessEvaluation of Plasma Catestatin Levels in Patients with Heart Failure: A Cross-Sectional Analytical Study
Objective: Heart failure (HF) is a common and potentially fatal clinical condition. Catestatin, a peptide derived from chromogranin A (CgA), inhibits catecholamine secretion. This study aimed to evaluate differences in plasma catestatin levels between individuals without HF and patients with HF, and to investigate the relationship between catestatin and established HF markers. GB, RE, IE, BY, RA, TO, FNA, KS Methods: A total of 60 HF patients with left ventricular ejection fraction (LVEF) ≤45% and 53 control subjects matched for factors that could influence catestatin levels were included. The absence of heart failure in control participants was confirmed by clinical assessment, review of medical records and transthoracic echocardiography. Plasma samples were collected simultaneously in aprotinin-containing tubes to prevent peptide degradation. Plasma catestatin levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: Catestatin levels were significantly higher in patients with HF (45.46 ± 16.69 ng/mL) compared with individuals without HF (37.15 ± 16.36 ng/mL) (t = 2.69, p = 0.008). Catestatin levels increased significantly with advancing NYHA functional class (Jonckheere–Terpstra test: J-T = 2.19; p = 0.029). Catestatin was positively correlated with NT-proBNP (r = 0.241; p = 0.010) and negatively correlated with LVEF (r = −0.19; p = 0.043). Catestatin was lower in patients with left ventricular hypertrophy than in those without, both within the patient group (41.39 ± 16.69 versus 49.64 ± 15.09 ng/mL; p = 0.04) and across the whole study population (37.41 ± 16.22 versus 44.04 ± 15.48 ng/mL; p = 0.03). The area under the ROC curve for catestatin in HF diagnosis was 0.635. Conclusion: Catestatin levels are associated with the presence and severity of heart failure. Its correlation with established parameters of severity and its progressive increase across NYHA functional classes indicate that catestatin may have value as a complementary neurohumoral marker in heart failure. Because the design was cross-sectional, no inference can be drawn regarding prognostic utility, and prospective evaluation is required.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (2) , 167-170
Peritonitis due to brucellosis in a patient newly diagnosed with liver cirrhosis complicated by ascites: A case report and literature review
Brucellosis is a common zoonotic disease with a wide variety of clinical manifestations. Spontaneous bacterial peritonitis (SBP) is a rare form among them. Here, we present the case of a 63-year-old woman with newly diagnosed liver cirrhosis complicated with ascites and diagnosed as spontaneous bacterial peritonitis with Brucella spp. growth in culture, and the literature is reviewed.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (2) , 167-170
Peritonitis due to brucellosis in a patient newly diagnosed with liver cirrhosis complicated by ascites: A case report and literature review
Brucellosis is a common zoonotic disease with a wide variety of clinical manifestations. Spontaneous bacterial peritonitis (SBP) is a rare form among them. Here, we present the case of a 63-year-old woman with newly diagnosed liver cirrhosis complicated with ascites and diagnosed as spontaneous bacterial peritonitis with Brucella spp. growth in culture, and the literature is reviewed.
- Open Access
- 19 February 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-8
The efficacy and comparison of upper gastrointestinal bleeding risk scoring systems on predicting clinical outcomes among emergency unit patients
Gastrointestinal bleeding is a significant cause of morbidity and mortality among emergency unit patients. Several scoring systems are verified for predicting hospitalization and mortality such as Glasgow Blatchford Bleeding Score (GBS), AIMS65 score, Rockall score (RS), and International Bleeding Risk Score (INBS; ABC score). The aim of this study is to evaluate the efficacy and predictive value of these scoring systems. Adult emergency unit patients with gastrointestinal bleeding were retrospectively enrolled. The age, gender, complaints at admission, vitals and examination results, laboratory findings, outcomes, blood transfusion status, and endoscopic interventions were all reported, and GBS, AIMS65, RS, and INBS (ABC) scores were calculated individually for all enrollies. A total of 311 patients were included. The median age of participants was 70 years (IQR (25–75%): 59–81), and 202 (65%) of them were male. The efficacy of all four scoring systems (GBS, AIMS65, RS, and INBS (ABC)) in predicting hospitalization, need of blood transfusion, determination of high- and low-risk patients, and mortality was found to be statistically significant (p < 0.05 for all). ROC-AUC analysis was revealed that while GBS is the most beneficial in predicting hospitalization, INBS (ABC) has the best predictive value on mortality. Besides, the only scoring model with predictive value in determining the need for endoscopic intervention was RS (p < 0.05). The present study showed that, among adult emergency unit patients with gastrointestinal bleeding, GBS, AIMS65, RS, and INBS (ABC) scores could successfully predict hospitalization, need of blood transfusion, determination of high- and low-risk patients, and mortality. However, the only scoring system that could be used to determine the need of endoscopic intervention is RS. Finally, we believe further studies with prospective enrollment would be beneficial for more accurate conclusions.
- 19 February 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-8
Open AccessThe efficacy and comparison of upper gastrointestinal bleeding risk scoring systems on predicting clinical outcomes among emergency unit patients
Gastrointestinal bleeding is a significant cause of morbidity and mortality among emergency unit patients. Several scoring systems are verified for predicting hospitalization and mortality such as Glasgow Blatchford Bleeding Score (GBS), AIMS65 score, Rockall score (RS), and International Bleeding Risk Score (INBS; ABC score). The aim of this study is to evaluate the efficacy and predictive value of these scoring systems. Adult emergency unit patients with gastrointestinal bleeding were retrospectively enrolled. The age, gender, complaints at admission, vitals and examination results, laboratory findings, outcomes, blood transfusion status, and endoscopic interventions were all reported, and GBS, AIMS65, RS, and INBS (ABC) scores were calculated individually for all enrollies. A total of 311 patients were included. The median age of participants was 70 years (IQR (25–75%): 59–81), and 202 (65%) of them were male. The efficacy of all four scoring systems (GBS, AIMS65, RS, and INBS (ABC)) in predicting hospitalization, need of blood transfusion, determination of high- and low-risk patients, and mortality was found to be statistically significant (p < 0.05 for all). ROC-AUC analysis was revealed that while GBS is the most beneficial in predicting hospitalization, INBS (ABC) has the best predictive value on mortality. Besides, the only scoring model with predictive value in determining the need for endoscopic intervention was RS (p < 0.05). The present study showed that, among adult emergency unit patients with gastrointestinal bleeding, GBS, AIMS65, RS, and INBS (ABC) scores could successfully predict hospitalization, need of blood transfusion, determination of high- and low-risk patients, and mortality. However, the only scoring system that could be used to determine the need of endoscopic intervention is RS. Finally, we believe further studies with prospective enrollment would be beneficial for more accurate conclusions.
- 18 March 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (SI-1) , 17-22
Treatment Of Variceal Bleeding
Cirrhosis is termed as the late stage of progressive hepatic fibrosis characterized by the disruption of the hepatic parenchymal structure and the formation of regenerative nodules. Many factors play a role in the etiology of cirrhosis. Currently, mortality is still high and causes significant work loss. The prognosis of patients with cirrhosis is largely due to its complications. Treatment of cirrhosis is limited except liver transplantation. An important cause of the morbidity and mortality associated with cirrhosis is the development of variceal bleeding secondary to portal hypertension. The prognosis of patients with variceal bleeding depends on the bleeding or other complications is associated with underlying chronic liver disease and its management. The mortality rate due to active variceal bleeding is around 20 percent during each bleeding and re-bleeding is observed in 70 percent of patients within one year. Upper gastrointestinal bleeding unrelated to portal hypertension is also common in patients with portal hypertension (eg, peptic ulcer disease). In this article, we will talk about variceal bleeding secondary to portal hypertension and its treatment based on current data.
- 18 March 2021
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 38 (SI-1) , 17-22
Treatment Of Variceal Bleeding
Cirrhosis is termed as the late stage of progressive hepatic fibrosis characterized by the disruption of the hepatic parenchymal structure and the formation of regenerative nodules. Many factors play a role in the etiology of cirrhosis. Currently, mortality is still high and causes significant work loss. The prognosis of patients with cirrhosis is largely due to its complications. Treatment of cirrhosis is limited except liver transplantation. An important cause of the morbidity and mortality associated with cirrhosis is the development of variceal bleeding secondary to portal hypertension. The prognosis of patients with variceal bleeding depends on the bleeding or other complications is associated with underlying chronic liver disease and its management. The mortality rate due to active variceal bleeding is around 20 percent during each bleeding and re-bleeding is observed in 70 percent of patients within one year. Upper gastrointestinal bleeding unrelated to portal hypertension is also common in patients with portal hypertension (eg, peptic ulcer disease). In this article, we will talk about variceal bleeding secondary to portal hypertension and its treatment based on current data.